官方服务：
资源简介：
Data of infants eligible for screening in 4 study SNCUs
应用场景：
创建时间：
2020-09-27
相关数据集
Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity
ABSTRACT Purpose: To compare the efficacy of intravitreal ranibizumab and bevacizumab treatment for type 1 retinopathy of prematurity (ROP). Methods: 36 eyes of 20 patients with type 1 ROP who receive
DataCite Commons2020-08-28 更新130
Supplementary Material for: Repeat Intravitreal Bevacizumab in a Very Low Birth Weight Infant with Recurrent ROP: 3-Year Follow-Up and Literature Review
Purpose: Low gestational birth weight is associated with increased incidence of Retinopathy of Prematurity (ROP). In recent years, intravitreal injection of anti-vascular endothelial growth factor (VE
DataCite Commons2025-06-13 更新50
Neonatal characteristics of infants treated with bevacizumab versus the control (2008–2014).
Neonatal characteristics of infants treated with bevacizumab versus the control (2008–2014).
NIAID Data Ecosystem40
Circular RNA Profiling in Peripheral Blood Mononuclear Cells from Retinopathy of Prematurity. Circular RNA Profiling in Peripheral Blood Mononuclear Cells from Retinopathy of Prematurity
To reveal the altered expression profiles of circular RNAs (circRNAs) in the peripheral blood mononuclear cells (PBMCs) of patients with retinopathy of prematurity (ROP), microarray analysis was condu
NIAID Data Ecosystem50
